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ABSTRACT
Forensic psychiatry in Europe is a specialty primarily concerned with individuals who have
either offended or present a risk of doing so, and who also suffer from a psychiatric condition.
These mentally disordered offenders (MDOs) are often cared for in secure psychiatric
environments or prisons. In this guidance paper we first present on overview of the field of
forensic psychiatry from a European perspective. We then present a review of the literature
summarising the evidence on the assessment and treatment of MDOs under the following
headings: The role of the forensic psychiatrist as an expert witness, risk assessment,
treatment settings for MDOs, and effectiveness of psychological and pharmacological
interventions. We undertook a rapid review of the literature with search terms related to:
forensic psychiatry, review articles, randomised controlled trials and best practice. We
searched the Medline, Embase, PsycINFO, and Cochrane library databases from 2000
onwards for adult groups only. We scrutinised publications for additional relevant literature,
and searched the websites of relevant professional organisations for policies, statements or
guidance of interest. We present the findings of the scientific literature as well as
recommendations for best practice drawing additionally from the guidance documents
identified. We found that the evidence base for forensic-psychiatric practice is weak though
there is some evidence to suggest that psychiatric care produces better outcomes than
criminal justice detention only. Practitioners need to follow general psychiatric guidance as
well as that for offenders, adapted for the complex needs of this patient group, paying
particular attention to long-term detention and ethical issues.
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1. INTRODUCTION
1.1 Aims
The aim of this guidance paper is threefold: Firstly, we give an overview of the field of forensic
psychiatry (1.2 – 1.5). Secondly, we provide a literature review of the evidence base and best
practice regarding the assessment and treatment of MDOs under the following headings: the
role of the forensic psychiatrist as expert witness, risk assessment, treatment settings for
MDOs, and effectiveness of psychological and pharmacological interventions, based on
articles pertaining to reviews, randomised controlled trials and publications on best practice
(3.2 – 3.5). We incorporate recommendations for best practice in forensic-psychiatric care
based on the scientific literature as well as the guidance identified.
1.2 Mental disorder and crime
Up until the 1980ies most professionals believed that there was no link between mental
disorders and violence (e.g. [1]). Several large scale epidemiological studies have since
resulted in a reappraisal of this position. One example of an early study that helped to reshape
opinion is the Epidemiological Catchment Area (ECA) study [2] a cross-sectional,
retrospective survey comprising a community sample of over 17 000 participants in five large
US cities. Based on self-report, the study found a lifetime prevalence of violence of 7.3% in
those with no psychiatric disorders whereas this figure was 16.1% in those with serious mental
illness (schizophrenia or major affective disorders) and rose to 35% in those with substance
misuse disorders; individuals with mental illness and substance misuse had a lifetime
prevalence of violence of 43.6%. This suggests that, while major mental illness appears to be
related with violence, substance misuse may have a much more significant role in increasing
the likelihood of committing a violent act. This importance of substance misuse was also
shown in the MacArthur Violence Risk Assessment Study (e.g. [3]) which followed up over
1000 patients discharged from psychiatric care and used different methods of collating
information on violence (self-report, carers’ report and criminal records). The study found no
significant difference between the prevalence of violence in patients and others living in the
same neighborhood when only looking at individuals without substance abuse. Substance
misuse raised the rate of violence in both patients and healthy individuals but did so
disproportionately in the patient group, suggesting substance misuse acts as a mediator
between mental illness and violence.
More recently a number of meta-analyses have synthesized data available on the relationship
between mental disorders and violence (e.g. [4-8]). These reviews, drawing on a large number
of primary studies (e.g. over 200 for schizophrenia), conclude that schizophrenia, other
psychoses and bipolar disorder are all associated with violence. However, large variations
were identified with odds ratios between 1 and 7 for schizophrenia in males and between 4
and 27 for females. For bipolar disorder, odds ratio estimates ranged from 2 to 9. Importantly,
for both disorders comorbid substance abuse increased odds ratios up to threefold, and for
bipolar disorder the significant relationship with violence disappeared when controlling for
substance misuse. For all serious mental illness diagnoses substance misuse played a more
significant role in increasing the risk for violence compared to the illness. Personality disorders
(PD) also appear to increase the risk of violent behaviour by threefold compared to individuals
with no such disorder, and in offenders those with PD have a higher risk of re-offending
compared to those without though outcomes differ greatly by PD type. Treated individuals,
offenders and MDOs, have improved outcomes (reduced reoffending rates; e.g. [9, 10] as will
be expanded upon below. This is also the case for pharmacological interventions which have
been shown to reduce reoffending in a national register study of 82 647 patients [11].
1.3 Forensic Psychiatry
Forensic psychiatry is a subspecialty of clinical psychiatry which requires special legal and
criminological knowledge as well as experience in the treatment of often complex and multiple
mental disorders. While the US tradition focuses on the role of the forensic psychiatrist in the
legal context and includes civil law matters [12], European forensic psychiatry takes a slightly
different perspective, emphasising the treatment of mentally disordered offenders (MDOs).
Gunn and Taylor argue that issues of victimisation and deprivation are essential to engage
with in order to both help those affected and to prevent future harm [13]. They define forensic
psychiatry as: “a specialty of medicine, based on a detailed knowledge of relevant legal issues,
criminal and civil justice systems; its purpose is the care and treatment of mentally disordered
offenders and others requiring similar services, including risk assessment and management,
and the prevention of future victimization.” (p.1).
The specialty is primarily concerned with individuals who have either offended or present a
risk of doing so, and who also suffer from a psychiatric condition. These MDOs almost
invariably have histories of psychosocial deprivation, including poor parenting, frequent
changes in caregivers, having being in care, having suffered abuse, poor education, and
unemployment, to name but a few [14]. They commonly have histories of substance misuse
and have often had multiple admissions to psychiatric services as well as previous contact
with the criminal justice system before coming into forensic-psychiatric care [15].
Due to their backgrounds, namely their offending histories, MDOs are often cared for in secure
environments, either in prison or in dedicated forensic-psychiatric hospitals. These institutions
are high cost-low volume services that may detain their clientele for long periods of time in
highly restrictive conditions (for a review of length of stay in forensic psychiatric institutions
see [16]). The purpose of this detention is seen as twofold: care and treatment for the patient
(for their own sake as well as in order to reduce future risk) and protection of the public from
harm from the offender. This dual role can cause dilemmas for the practitioner as described
by Robertson and Walter for psychiatry as specialty as a whole, though this is more acutely
felt in the forensic context: “In psychiatric ethics, the dual-role dilemma refers to the tension
between psychiatrists' obligations of beneficence towards their patients, and conflicting
obligations to the community, third parties, other health-care workers, or the pursuit of
knowledge in the field. These conflicting obligations present a conflict of interest in that the
expectations of the psychiatrist, other than those related to patients’ best interests, are so
compelling. This tension illustrates how the discourse in psychiatric ethics is embedded in the
social and cultural context of the situations encountered. It appears that as society changes
in its approach to the value of liberal autonomy and the 'collective good', psychiatrists may
also need to change”. [17] (p.228).
1.4 The role of a forensic psychiatrist
As is the case in all medical specialties, it is the medical doctor whose duty it is to bring clinical
leadership to forensic psychiatry [18], and to have a pivotal role in defining service delivery for
MDOs and others requiring similar services on a more general level [19]. Thus, although legal
and clinical frameworks differ across Europe, forensic psychiatrists have similar roles, such
as
 providing treatment for severely mentally ill people who offend,
 working effectively at the interface of law and psychiatry, and, in so doing, working with
other clinical and non-clinical professionals in the field,
 providing reports and giving evidence to courts, and
 assessing and managing the risk of MDOs and preventing reoffending.
In order to fulfil these roles, forensic psychiatrists must have specialist knowledge and skills,
namely in the assessment and management of complex mental disorders, violence and sexual
deviance, and the risks that these behavioral phenomena pose. To this end, the forensic
psychiatrist must be able to incorporate academic and clinical skills, techniques and research
developed in neighboring disciplines, such as youth, adult, and geriatric psychiatry,
psychology and criminology [20]. Furthermore, the forensic psychiatrist must adapt to the role
of being an objective evaluator in addition to providing psychiatric care to patients [21].
However, although forensic psychiatrists may cross the border from empirical medical science
into the court room and may act on behalf of courts or administrations when they treat their
patients, the patient is still at the core of what they do. This notwithstanding, forensic
psychiatrists are interpreters of medical and psychological findings for judges, prosecutors,
lawyers and administrators, so that they can, in turn, better understand them and apply
relevant legislation accordingly. It is vital that forensic psychiatrists are, however, aware of the
risk that their dual role could become unduly slanted towards the legal framework they operate
within, rather than by their medical ethics. Thus, as is stipulated for all healthcare
professionals, forensic psychiatrists are ethically bound by the standards set by their
professional bodies and, indeed, judged to be guilty of misconduct if they deviate from these
standards due to pressures from the courts, penal institutions or other societal interest groups
[22]. This robust professionalism [23, 24] also includes refraining from commenting on issues
beyond their expertise or that breach confidentiality.
These elements inherent in the role of the forensic psychiatrist are even more pronounced in
leadership positions. By deciding on issues such as referral, discharge, recall and triage
criteria [25, 26] and appropriate levels of security [27], directors of forensic units are, in effect,
participating in defining which behavioral issues that society faces should be treated within
general psychiatric services, forensic services or the penal system, i.e. how society’s forensic
population is to be demarcated. To this end, forensic psychiatrists’ roles inevitably require
restricting a person's liberty, at least in the short term, and thus present the clinician and
society in general with many inherent clinical and ethical challenges. However, ultimately, the
basic aims of care delivery in forensic psychiatric settings are essentially the same as in the
community and in medicine in general: to diminish pain and suffering and empower the
individual to function healthily and freely in society.
1.5 A European perspective on forensic psychiatry
Forensic psychiatry operates within the legal and societal context of a country and is therefore
subject to the wider influences and trends of that society, e. g. the attitudes towards offenders
- exclusion or incapacitation on the one hand or offender rehabilitation on the other. Laws –
rules that guide human behaviour – differ from the scientific frameworks clinicians are
otherwise used to dealing with in that they are man-made and normative, and as such can be
changed at any time. The rules relevant to the detention of and care for MDOs differ widely
across Europe though there is some common ground [28, 29].
All European legislations recognise the concept of criminal responsibility as a prerequisite for
punishment. Individuals who lack responsibility for the act they have committed are therefore
exempt from punishment which usually results in admission to a treatment facility (or acquittal)
rather than punishment. Most, but not all, countries recognise some grading of that
responsibility, that is an individual is not only seen as either fully responsible or completely
irresponsible for their actions but can be of diminished responsibility. Such diminished
responsibility, where it is recognised, can then result in a less severe punishment, i.e. a shorter
sentence of imprisonment.
Most European countries require some degree of reduced responsibility for entry into the
forensic-psychiatric system while individuals with full responsibility for the crime committed will
be subject to punishment, even if they did suffer from a mental disorder at the time of the act.
However, in some countries, e.g. the UK, access to forensic psychiatric care is independent
of criminal responsibility and determined only on the basis of the mental condition at the time
of assessment. A number of national laws within Europe provide exclusion criteria for
detention in a psychiatric, including forensic-psychiatric hospital, e. g. personality disorders,
substance use disorders or sexual deviancy. This may be welcome from a civil liberty
perspective as it means subjecting fewer people to the restrictions of compulsory psychiatric
care and detention; on the other hand, such exclusion might also result in a lack of service
provision for those in need.
Given the above, it is not surprising that rates of detention within the EU vary widely from
country to country. This is apparent in figures of imprisonment where Eastern European
countries show imprisonment rates of over 200 per 100 000 inhabitants; England & Wales
takes the lead amongst Western European countries with nearly 150 whilst lowest
imprisonment rates are found in Northern European countries with figures ranging from about
40 to 70 per 100 000 [30]. Figures for forensic-psychiatric beds are more difficult to obtain.
Salize and colleagues compared forensic bed rates in 15 EU countries and found variations
from 0.8 / 100 000 (France) to 13.1 / 100 000 (Germany) [28]. Only one other country (Belgium)
reported more than 10 beds / 100 000 while six countries indicated figures of less than 5 / 100
000 (Austria, Greece, Ireland, Italy, Portugal and Spain). For Eastern European countries,
Mundt and colleagues described a mixed picture with increases in forensic bed numbers
between 1999 and 2009 in some countries (e.g. Hungary, Poland) and decreases in others
(e.g. Czech Republic, Latvia) [31]. Chow and Priebe [32] provided more up to date figures for
eleven Western European countries describing changes in bed numbers from 1990 to 2012.
In all countries forensic bed numbers / 100 000 increased, in some cases dramatically. E.g.,
Austria, Belgium, Ireland and Germany all started with less 5 / 100 000 in 1990 but at the end
of the study period had between 8 and 12 forensic beds / 100 000 population. Countries with
lower numbers, under 3 / 100 000 throughout, were Italy, Spain, Switzerland and the UK.
During the same period, general psychiatric beds decreased while places in other institutions,
including protected housing and prisons, also increased though the authors could not
evidence a causal link between these different trends (which was suggested to exist in the so-
called Penrose hypothesis).
Most countries allow detention of MDOs beyond the length of prison sentence their offence
would have attracted had they been imprisoned [33]. However, some – Croatia, Italy, Portugal
– limit the time of psychiatric detention to the time the individual would have served had they
not been mentally disordered and had received a custodial sentence. In other countries (e.g.
Germany) it is recognised that the longer the detention in a forensic-psychiatric facility the
more relevant considerations of proportionality become with the patients’ right to freedom
being balanced against any risk they may pose [29].
Outpatient services for forensic patients are available in some countries though information
about its use is patchy. Salize and Dreßing [34] note that outpatient services are available in
four countries: Austria, Belgium, Germany and the Netherlands; since their publication they
have also been introduced in the UK [35] and in Poland [36].
2. METHOD
We undertook a rapid review of the literature regarding the topics relevant to this paper as
described in 1.1 Aims. Rapid reviews are an emerging form of knowledge synthesis aiming ‘to
inform health-related policy decisions and discussions, especially when information needs are
immediate’ [37]; ‘components of the systematic review process are simplified or omitted to
produce information in a short period of time’ [38]. Despite the somewhat truncated process,
rapid reviews maintain the key steps of a systematic review in terms of identification of a
research question and search strategy and identification, screening, selection and
summarising of relevant studies [38]; and they have been found to maintain the essential
conclusions compared to those produced by a full systematic review [39].
We undertook a literature search based on the following concepts: forensic psychiatry, review
articles, randomised controlled trials and best practice. Both textword and MeSH categories
were used as search terms in the following databases: Medline, Embase, PsycINFO, and the
Cochrane library. Searches were conducted for a timeframe from 2000 onwards for adult
groups only. No restrictions were placed on language or publication type. Included publications
were scrutinised for additional relevant literature, including earlier publications of interest.
Please see Table 1 for the full search strategy.
In addition to bibliographic databases, we searched the websites of relevant professional
organisations for policies, statements or guidance of interest: European Committee for the
Prevention of Torture and Inhuman or Degrading Treatment or Punishment, European
Cooperation in Science and Technology, European Psychiatric Association, National Institute
for Health and Care Excellence, Royal College of Psychiatrists and the World Psychiatric
Association.
We have written to the forensic sections of psychiatric membership organisations of the EPA
for comments on the topics covered in this paper as well as to enquire about any guidance
papers that might exist on forensic psychiatry in their countries. The response was limited and
resources did not allow the translation of national guidance documents. We have also
consulted the individual members of the Forensic Section of the EPA, who made additional
comments on content and relevant literature as well as commented on guidance in their
countries. The final version of the paper was approved by the Board of the EPA Forensic
Section.
3. RESULTS
3.1 Results of searches
In total, 6310 references were retrieved from Psycinfo (n = 1377), Medline (n = 2271), Embase
(n = 2265) and Cochrane (n = 9). This was reduced to 4422 after deduplication. Initially 170
abstracts and summaries were identified for inspection, from which 117 papers were selected
for further consideration. An additional 71 reports and papers were identified during the
website searches and downloaded for consideration.
Forty-five papers from the database searches and 16 documents from web searches were
selected for inclusion of which the main themes were treatment/intervention (n = 25), prison
psychiatry (n = 11), risk assessment (n = 7), service provision (n = 4), community treatment (n
= 3), liaison/diversion (n = 2), European perspectives (n = 2), outcomes (n = 2), ethics (n = 2),
role of the psychiatrist (n = 2) and models (n = 1). However, several papers were relevant to
multiple themes. The scientific papers and guidance papers we identified through the searches
are indicated in the references list with one asterisk (*).
3.2 The forensic psychiatrist as expert witness
As outlined above, the role of a forensic psychiatrist may include acting as expert witness in
court, providing evidence on issues of criminal responsibility, treatability and risk of violence.
The determination of criminal responsibility is in many countries the most usual form of
assessment requiring forensic expertise. This typically involves the identification of any mental
disorder the examinee might suffer from and determining whether this disorder was present
at the time of the crime. Furthermore, it will be necessary to assess the impact of the
examinee’s mental state at the time of the offence on his or her capability to appreciate the
legal wrongfulness of the act and/or his/her ability to act accordingly [40, 41]. Given the
significant implications such assessments might have for the person assessed, it is essential
that reports provided to court are carried out to high standard and within an ethical framework
[42]. Various national medicolegal authorities [43-45] and The World Psychiatric Association
have provided guidance on such work [46]. These include guidance on the various stages of
the process, from the request to provide a report to gathering evidence and interviewing the
examinee, the structure of the report and the subsequent appearance in court. Details can be
obtained on the WPA website, though the key principles of the guidance include:
 Clarity needs to be sought with regards to the details of the request to provide a
medico-legal report, including its legitimacy and whether it falls within the expert’s area
of expertise.
 The expert is obliged to provide an unbiased report and not act as an advocate for the
examinee. The WPA guidance therefore recommends that the medico-legal expert
should not be the treating doctor of the examinee (though others having taken a
different view, e.g. [47].
 Prior to working on the report, the expert should obtain the agreement of the examinee,
based on informed consent, including informing them of the consequences of
cooperating or not cooperating. It is important that the examinee understands that the
process is different to a therapeutic consultation and that no treatment will be provided
by the expert.
 Principles of confidentiality do also apply in this context and any information not
relevant to the purpose of the report must not be disclosed.
 The report should be based on sufficient information and all relevant information on
which the conclusions rely upon should be disclosed. It is desirable to obtain third party
information.
 The assessment should be undertaken in person.
 The report should explain any medical terms used so that its content is comprehensible
to non-medically trained readers.
 Regarding the use of any instruments, including for risk, the expert needs to be aware,
and make clear in the report, their applicability to the case assessed and any other
limitations of their use.
 Guidance is also provided as to the structure and detailed content of medico-legal
reports though it is beyond the scope of the paper to repeat this here. Importantly, it is
highlighted that a report does not just consist of listing the facts and results of any
examinations but should provide a formulation, an explanatory synthesis of the case,
offering a biopsychosocial explanation of the presumptive causative factors in the
examinee’s offending and risk.
 It is important that the expert highlights any uncertainties of the case and any
inconsistencies between subjective report and objective findings and how this may
impact on the final opinion.
Specific guidance regarding feigning of symptoms is provided by Gottfried and colleagues
[48]. This emphasizes the importance of collateral information. No instruments exist to
evaluate retrospective feigning of symptoms at the time of crime, and the use of general
malingering measures such as the Structured Interview of Reported Symptoms is
recommended.
Finally, it is important for the expert to be aware that they are there to advise the court but the
ultimate decision, e.g. regarding criminal responsibility, is determined not by the expert but by
the court.
In most work carried out as a forensic psychiatric expert witness, it is essential to refer to the
use of formal assessment tools (see Risk). The assessment of issues such as legal and
functional mental capacity, various forms of behavioral risk and recommendations for
discharge, have also been rendered more amenable to research and scientific enquiry [49] by
the use of validated actuarial and structured professional judgement tools, thus providing a
more justified basis for expert evidence and legal decision making in the context of, arguably,
increasingly risk-conscious European societies [50, 51].
3.3 Risk
Thorough assessment of risk and protective factors is crucial for risk appraisal and the
prevention of recidivism. Risk assessments are required both in the context of providing
expertise to courts as well as in the planning of interventions for MDOs. The risk principle of
the Risk Needs Responsivity (RNR) model necessitates having reliable and valid risk
assessments to assign individuals to treatment programmes based on their risk [52].
Risk can be assessed using unstructured clinical assessments, actuarial risk assessments
(ARA) and structured professional judgements (SPJ) [53, 54]. Unstructured assessments are
subjective and have demonstrated poor predictive ability [54]. ARAs and SPJs have been
developed to improve the predictive validity of risk measures. In ARA, a set of risk factors is
statistically combined in a fixed, mechanical way, often then providing a numerical outcome
regarding the likelihood of, e.g., future violence [54-56]. SPJ approaches moved away from
the reliance on static variables to include also dynamic variables and give professionals the
flexibility to modify the overall risk level [57]. Dynamic factors may be amenable to treatment
and therefore SPJs can be used to identify and inform treatment targets. For example, the
Violence Risk Scale (VRS) (e.g., [58] contains six static and 20 dynamic risk factors. The HCR-
20 (now Version 3; [59]) contains 10 static, historical factors and 10 dynamic factors, five
pertaining to recent clinical functioning and five considering future risk management. Empirical
evidence suggests that both ARA and SJP perspectives have similar predictive validity [56,
60]. Coid and colleagues drew similar conclusions but also found that, in respect to men,
actuarial measures outperformed SPJs in predicting violent reoffending [61].
Pre-treatment ratings on the dynamic factors can be used to represent treatment targets and
post-treatment ratings can be used to assess progress, but only if these dynamic factors not
only have predictive validity but changes in these factors tap into the causal mechanism of
criminal behaviour and result in changes of behaviour [62]. Causal instead of predictive
models should therefore be preferred in the implementation of clinical risk management [63].
There are a large number of specific risk assessments tools in use. A systematic review of the
literature [64] identified 80 different variables used in the measurement of violent or sexual
recidivism and 20 formal assessment instruments. A review of surveys on the use of violent
risk assessment tools, published between 2000 and 2013, identified nine surveys, mostly from
the US and the UK [65]. A more recent global survey of 44 countries reported the use of 400
instruments [55]. The HCR-20 [Version 2: 66; Version 3: 59] was identified as the most
commonly used instrument both in Europe and internationally in both studies, followed by the
Psychopathy Checklist Revised (PCL-R) [67].
A meta-analysis of violence risk assessment tools, reviewing 68 studies pertaining to nine
different risk assessment tools, found that the Psychopathy Checklist Revised (PCL-R)
produced the lowest rate of predictive validity; however, it is of note that this instrument was
designed as a clinical rather than a risk assessment tool [68]. The highest rates of predictive
validity were found in instruments designed for specific rather than more general populations,
e.g. for sex offenders, and in older and in predominantly white samples [68]. Additionally,
neither ARA nor SPJ measures produced better levels of predictive validity. However, from a
clinical point of view, the flexibility afforded by SPJ approaches along with its potential utility
in treatment planning has led to a preference of practitioners of these approaches. In criminal
justice settings, the picture is slightly different though, with ARA measures being used more
widely, in particular in the assessment of sex offender risk [69]. For sex offender risk
assessment, this preference is supported by a review of 118 prediction studies [70],
concluding that ARA measures outperformed SPJ approaches in the prediction of sexual
recidivism.
There are concerns about the high number of false positives — individuals who incorrectly are
considered having a high risk of reoffending — which may lead to additional treatments or
restrictions to liberty. Consequently, a further systematic review explored the predictive
accuracy of the most commonly used risk assessment instruments [53]. The review found that
tools are effective at screening out individuals at low risk of reoffending but only have low to
moderate positive predictive value [53]. Fazel and colleagues stated that “even after 30 years
of development, the view that violence, sexual, or criminal risk can be predicted in most cases
is not evidence based.” (p.5) [53]. The review concluded that the tools perform moderately
well for informing treatment but are limited if used as the sole determinant of sentencing or
release decisions [53]. The need to be cautious in the use of risk assessment instruments for
individual clinical decisions is compounded by the low and varying base rates for violent
recidivism in the local population of which the assessed person is a member and the assessed
person is compared with [71]. Caution is also warranted in the application of risk assessment
tools in specific populations such as women (e.g. [72]) or those with intellectual disability [73]
as psychometric properties might vary across groups.
Forensic risk assessment models generally focus on risk rather than protective factors [74,
75]. Therefore, others have sought to emphasise protective factors [76]. For example, the 17-
item Structured Assessment of PROtective Factors for violence risk (SAPROF) [77, 78] was
developed to be used alongside the HCR-20. The SAPROF may also have predictive validity
for sexual offending as well as other violent offending although more evidence is required [79].
Although their predictive validity seems not to outperform the validity of risk focused
assessment tools, strength based tools may improve the predictive validity of risk oriented
approaches and contribute to the desistance from crime [79]. Consideration of protective
factors is consistent with clinical practices such as rehabilitation and recovery and may have
a positive effect on the motivation to participate in treatment [57]. This consideration is
underlined by a study from Abbiati and colleagues [80] in which, in contrast to previous
findings, none of the subscales of the SAPROF showed predictive validity, except for
‘Motivation’. Although the use of protective factors in assessing risk is in its infancy, the
evidence base is limited and some authors state that the relevance of these factors can be
found elsewhere, like the development of a therapeutic relationship, the influence of protective
factors deserves more scientific attention [81].
Violence risk assessment is a global phenomenon, yet its utility in clinical practice has not
been evaluated thoroughly. E.g., Singh et al’s survey found that, overall, raters received
feedback about the outcome of their assesses in fewer than 40% of cases; where
assessments were completed to inform management plans, feedback was available in fewer
than 50% of cases and only in a third of cases were the plans implemented [53]. Obviously,
risk assessments will only reduce violence if they are communicated and related plans
implemented. More research is therefore needed regarding any obstacles in these areas. It
also remains largely untested as to whether embedding risk assessment and formulation into
clinical care prevents recidivism; the only RCT in this area so far [82] suggests this may not
be the case.
3.4 Treatment settings for mentally disordered offenders
Treatment for MDOs is provided in a number of settings - in the community, either as diversion
from custodial sentences or following release, in secure forensic-psychiatric hospitals of
different security levels, and in prison. Some countries have developed diversion schemes
which allow for he early detection of mental disorder, e.g. at the time of arrest or at appearance
in court [83]. This will then allow to either divert the person to the health system without the
involvement of the criminal justice system or for the court to take the individual’s mental health
needs into account when dealing with the case. Liaison and diversion services1, usually staffed
1 In the US a similar development took place with the introduction of Mental Health Court but to our knowledge
no such courts exist in Europe, although they have been piloted in the UK
(www.ohrn.nhs.uk/resource/policy/MentalHealthCourts2010.pdf ).
by mental health nurses and based either in police stations or at court, provide screening,
assessment and onward referral, or in some cases further support and management. Such
schemes have been found to improve mental health and reduce the risk of re-offending and
are therefore recommended for implementation (for a review see [83, 84]. Effective
coordination of the different agencies involved is key to the success of these services [85].
3.4.1 Treatment in the community
In the community, individuals with offending histories should have access to the same services
as their non-offending fellow citizens though some aspects of this treatment may not be
voluntary. For example, individuals may serve a community sentence with the requirement to
attend for mental health or substance misuse treatment. Equally, there are those who are
released on licence (conditionally released) and part of their licence conditions may be to
attend for particular treatments.
The importance of community services for MDOs is demonstrated by studies investigating the
prevalence of mental disorders in offenders in the community. Looking at probation
supervisees at various stages of engagement, Brooker and colleagues found that 15% had
had contact with mental health services in the preceding 12 months and 27% had been seen
by mental health services at some point in their lives [86]. Furthermore, an assessment of
needs in probation service areas and prison establishments in England and Wales found 45%
of offenders had emotional well-being needs [87].
However, there are some challenges in providing psychiatric services for offenders in the
community. Firstly, many have a complex mixture of social disadvantage as well as psychiatric
problems [88] and, in common with other such socially and psychiatrically disadvantaged
populations, they either do not access available services or, if they do so, such access is
intermittent and crisis driven following an overdose or injuries received in a fight [89]. For
instance, Brooker et al found that nearly 39% of offenders had visited an accident and
emergency department or an NHS walk in centre at least once in the previous 12 months [86].
Secondly, in countries where services are diagnostically defined, MDOs may be
disadvantaged as they may present with a range of sub-threshold pathologies which may not
meet the service criteria for individual services. For instance, they may have had brief
psychotic episodes, but not schizophrenia, and hence may not be accepted by a Community
Mental Health Team. Similarly, they may have borderline intelligence or mild learning disability
with not severe enough problems to meet criteria for learning disability services. The same is
the case for substance misuse where MDOs may abuse a range of substances without
developing dependency for any specific one and therefore they may not be able to access
substance misuse services. In addition, MDOs often suffer from personality disorders, a
diagnosis sometimes excluded from psychiatric services though changes have been made in
this respect in recent years [90].
It is not clear which model works best for MDOs in the community and whether compulsion
produces better outcomes. Given the complex needs of MDOs, assertive outreach models
(Assertive Community Treatment, ACT) of care have been applied to this patient group.
Jennings reviewed the evidence of such models, adapted for forensic populations, and
concluded that there was evidence for improvement in mental health but not offending
outcomes [91]. They recommend the provision of extended residential treatment with a focus
on life skills and treatment continuity prior to implementing ACT. A recent systematic review
of ACT trials, including 11 studies (3 RCTs, none based in Europe) also found only limited
support that ACT adapted for forensic populations improves forensic outcomes [92].
Community treatment orders (CTO) allow for compulsory treatment in the community, usually
following discharge from a hospital setting. However, research has failed to produce
convincing evidence that CTOs are superior to treatment as usual in terms of readmission
rates and other health outcomes (for a review see e.g. [93, 94]) and Kisely and colleagues
found that 238 CTOs would be needed to prevent one arrest [95].
3.4.2 Treatment in forensic-psychiatric in-patient settings
While provision of care in psychiatric settings is considerably more resource intensive than in
prison, there is some evidence from a systematic review of patient outcomes following
discharge from secure psychiatric hospitals that reoffending rates are lower when compared
to released prisoners [96]. Nevertheless, the major predictors of recidivism in MDOs have
been shown in a meta-analysis to be the same as for non-MDOs [97] suggesting that general
criminogenic needs might be more relevant in predicting outcome than mental disorders.
While it is possible for MDOs to be treated in general psychiatric settings in many countries,
they are usually admitted to specific forensic-psychiatric settings. A number of countries have
found forensic treatment beds to reduce in number, others have described an increase [98].
In England and Wales, e.g., the forensic-psychiatric population has increased by 45% between
1996 and 2006 and the length of stay has also risen. A recent study found that up to a quarter
of patients could be classified as ‘long-stay’ (length of stay more than 10 years in high or more
than 5 years in medium secure care) and some have little prospect of being released which
poses significant ethical issues [99]. Most countries provide forensic care at different levels of
security, reflecting the risk the patient poses [28]. While such levels of care can facilitate care
being provided in the least restrictive setting, they can also lead to inefficiencies and waiting
times, particularly where these different security levels are provided in completely separate
institutions as is the case, e.g., in England & Wales.
Services may also differ in terms of the patient groups they cater for. While in the Dutch
forensic-psychiatric system the majority of patients are diagnosed with a personality disorder,
other countries have been more reluctant to cater for this group. In England and Wales a pilot
service was developed in the early 2000ies for individuals with so-called Dangerous and
Severe Personality Disorders (DSPD), established partly in prison and partly in high secure
hospitals [100]. However, this service has now been decommissioned and there is an
expectation that interventions for personality disordered offenders are provided within the
criminal justice system.
Given the complexity of presentations of MDOs, the assessment of the effectiveness of
treatment in such institutions is also highly challenging. In addition to specific interventions,
which will be addressed below, attention has to be paid to the therapeutic milieu of the
institution itself. Given the nature of the population, security is an important element of care
and can be divided into structural or environmental, procedural and relational aspects [101].
Tapp and colleagues undertook a Delphi survey to identify the key elements of high secure
care [102]. In addition to the different elements of security, experts reached consensus on
some specific medical (clozapine), psychological (CBT based interventions) and social
interventions (e.g. off-ward activities) as well as general elements of care delivery
(multidisciplinary working, patient involvement) making a positive contribution to care in round
one of the survey. However, no consensus was reached on which of these aspects are
essential elements of care in any of the subsequent survey rounds. The same author group
undertook a systematic review of high secure care [103] identifying 22 studies (13 European).
Evidence for effectiveness was found for high secure care itself, third wave cognitive-
behaviourally based interventions, psychoeducation and antipsychotic interventions; however,
the evidence base is weak given that mainly small, single, non-RCT studies contributed to the
review.
3.4.3 Prison psychiatry
Even in countries where specialised institutions exist that allow for the redirection of MDOs
from the criminal justice to the healthcare system, most offenders with mental disorders are
found in prison settings. The high prevalence of mental disorders has been described in
numerous studies from different countries. Fazel and Danesh synthesized the findings from
62 surveys including nearly 23 000 prisoners from 12 countries, including nine in Europe [104],
and found that 3.7% of men (4% of women) had a diagnosis of psychotic illness, 10% of major
depression (12%), and 65% of PD (42%, mainly antisocial PD) – rates much higher than those
in the general population. For substance related disorders, based on 13 studies (though only
three based in Europe) including over 7 500 prisoners, estimates for alcohol abuse or
dependence ranged from 18 to 30%, and for drug abuse / dependence from 10 to 48%. The
increased risk of suicide in prisoners is of particular concern and is the leading cause of death
in penal institutions, especially during the early stage of confinement. An updated systematic
review of the prevalence of psychotic illness and major depression examined 109 samples
(38 European) including over 33 000 prisoners from 24 countries (14 European) [105]. Overall,
similar prevalence rates were found although there was an increase over time in depression
in the USA. Suicide rates per 100 000 prisoners have been found to range from 58 to 147 in
a review of studies from 12 studies from Western countries (9 European) compared to figures
from 16 to 31 in the general population [106].
Prisons are arguably places not conducive to mental well-being. Imprisonment is by its very
nature and design associated with the deprivation of liberty, restrictions to one’s life style and
autonomy, a loss of employment and accommodation, and, importantly, of relationships,
including with partners, parents and children. The environment itself may be perceived as
harsh and unsupportive and some prisoners, in particular those with sexual offences, may
experience bullying and victimization [107]. All these factors contribute to an increase or
exacerbation of mental health problems in prisons and therefore call for the implementation of
services to address these issues [108].
Whether or not mentally disordered persons should be treated in prison or hospital is a
primarily philosophical question and different countries have developed a range of approaches
to dealing with the issue of mental disorder and imprisonment. As described above, countries
applying the construct of criminal responsibility can prevent mentally disordered persons from
being imprisoned and instead divert them to the hospital system. Whether or not transfer of
prisoners to a hospital setting is possible depends largely on the legal system of the country.
Treatment of an acutely psychotic prisoner can in principle take place within a prison hospital
or ward or via transfer to a general or forensic psychiatric hospital. Most European countries
rely on a number of these options [109] though some have one option available only (e.g.
treatment only in prison hospitals in Belgium and Lithuania or exclusively via transfer to a
forensic-psychiatric hospital in Ireland).
For those prisoners treated within penal institutions (whether or not hospitalized within the
prison system), the principle of ‘equivalence’ with therapeutic provision matching that of care
in the community according with the development of psychiatric care in each country, should
prevail as has been mandated by a number of European and international conventions and
recommendations though it is doubtful whether the majority of prisoners with mental disorders
receive such care. In addition to funding and organisational issues, there are also challenges
with regards to the evidence-base of treatments in prisons, not least due to the significant
hurdles associated with running trials in these settings [110].
A number of international rules are applicable to the treatment of prisoners. Of these the
United Nations Standard Minimum Rules for the Treatment of Prisoners [111] as well as the
UN Convention on the Rights of Persons with Disabilities [112] are of most relevance
worldwide. Within Europe, the Council of Europe has developed recommendations on the
ethical and organizational aspects of healthcare in prison (Recommendation No R (98) 7)
[113] while the European Prison Rules (Recommendation Rec[2006]2) [114] specify that
prison conditions must not infringe human dignity; life in prison should approximate life in the
community (including equivalent healthcare) with restrictions only applied to the minimum
necessary. Furthermore, prisons should offer meaningful occupational activities and treatment
programmes, preparing for reintegration into society. The European Committee for the
Prevention of Torture and Inhuman or Degrading Treatment or Punishment [115] visits places
of detention, including prisons, and has also developed some standards for prison, e.g.
regarding health-care provision, living space per prisoner, solitary confinement and the
situation of life-sentenced prisoners.
In addition, a number of professional organisations have developed guidance documents
touching upon prison psychiatry, though these are by their nature recommendations and not
legally binding, e.g. the World Medical Association (esp. Declaration of Tokyo 1975) [116], the
World Psychiatric Association (esp. Declaration of Hawaii 1977) [117] and the International
Council of Prison Medical Services (Oath of Athens) [118]. More detailed guidance for doctors
working within the prison system is available in the consensus paper on prison psychiatry from
the forensic section of the World Psychiatric Association [119, 120] which stipulates:
 The principle of equivalence must prevail – prisoners must not be discriminated against
for being imprisoned and hence should have access to specialist mental health
treatment – based on a multidisciplinary team approach - including pharmacological
and psychological interventions, day-care, substance misuse treatment and in-patient
treatment.
 Individuals should not be excluded from accessing such treatment on the basis of
specific diagnoses or behaviour associated with such diagnoses, e.g. personality
disorders or substance misuse.
 Prisoners with serious mental disorders should either be transferred to a suitable
treatment facility outside prison or treated in a hospital wing within the prison.
 All prisoners should be screened for mental disorders, including substance misuse,
using a recognised, standardised tool, upon reception by appropriately trained
personal following a written procedure which outlines what actions need to be taken
as a result of the screening as necessary.
 Except for in emergency situations, consent to treatment must be sought and prisoners
who have the capacity to make informed treatment decisions must not be treated
against their will. This includes situations of self-inflicted harm, including hunger strike.
 Coercive measures, including forced medication, restraint, seclusion and solitary
confinement must be reduced to an absolute minimum. Clinicians must not use any of
these measures as a form of punishment and individuals subject to coercive measures
must be closely supervised to identify any ill effects of the intervention. The use of
these measures should follow written policies and procedures and be documented and
monitored (see also [121]).
 Principles of confidentiality also apply to prisoners and the treating physician must not
disclose confidential information to the prison authorities or any other agencies without
patient consent unless there is a clear legal provision to do so within the country.
 Mental health teams in prisons should carefully plan for a prisoner’s release by making
links to community services in good time and arrange for a full handover to take place.
 Prisons should consider the specific needs of vulnerable or marginalized groups which
may have specific mental health needs, including women, ethnic minorities,
immigrants, juveniles and sex offenders.
 The prison should be committed to mental health promotion and training of staff to
raise awareness of mental health issues and to minimise stigmatisation (see also
[122]).
Specifically for the prevention of suicide, the International Association for Suicide Prevention
Task Force on Suicide in Prison [123] has developed recommendations which provide helpful
guidance, emphasizing the need for training correctional staff to recognise suicide risk, the
importance of the general prison environment, including initiatives to reduce victimization,
good communication between staff and inmates, procedures for screening inmates for suicide
risk and for the observation of suicidal inmates, adjustments to the built environment, e.g.
removal of ligature points, procedures for the distribution of medication, debriefing after a
suicide has occurred, and providing sufficient resources for an effective suicide prevention
strategy.
3.5 What works for mentally disordered offenders
Caring for MDOs requires simultaneous consideration of: a) the needs for treatment resulting
from specific elements of the mental disorder and b) the needs for treatment with respect to
factors promoting criminal behaviour. Therefore, treatment programmes require multiple
components to address the complex needs of MDOs [124]. However, people are exposed to
various treatment agents and environmental influences and so it may not be feasible to
conduct rigorous controlled studies to assess the efficacy of specific treatments [124].
3.5.1 Psychological interventions
Correctional treatment was viewed negatively in the 1970ies when the findings from
Martinson’s paper “What works?” [125] contributed to the popular view that “nothing works”, a
view which endured through the 1980s [126]. Treatment programmes for MDOs are informed
by programmes for non-mentally disordered offenders and this evidence base at the time was
limited. Treatment programmes for MDOs in secure settings were poorly designed,
implemented and evaluated [127]. Since then, evidence has been provided for violence
reduction programmes and sexual offending programmes though in particular the evidence
for the latter is hotly debated still, and some argue the investment is not justified given the
relatively narrow margin of difference compared to non-treated populations.
The risk-need-responsivity (RNR) model [52, 128] has been an influential model of offender
assessment and rehabilitation. As suggested by its name, it is based on three principles: 1)
the risk principle asserts that criminal behaviour can be reliably predicted and that treatment
should focus on higher risk offenders; 2) the need principle highlights the importance of
criminogenic needs in the design and delivery of treatment; and 3) the responsivity principle
describes how the treatment should be provided. Despite the evidence base for the principles
of the RNR model in reducing recidivism, treatments for MDOs often do not adhere to its
principles [129]. Therapies are often adapted in content or delivery style to meet the needs of
individuals or groups of individuals [130]. These adaptations fit with RNR principles but
heterogeneity can make evaluating the efficacy of such therapies more difficult. In addition,
manualised treatments can restrict the ability to address the responsivity principle [131].
Other models include the strengths-based good lives model (GLM), which focuses on
improving how the offender functions as a person by enhancing his or her capabilities to attain
goals, or primary human goods, through socially acceptable means [132,133], and is
applicable for MDOs [74, 134]. Andrews and colleagues defended the principles of the RNR
model and rebutted criticism of the model by proponents of the GLM model [135]. For example,
they argue that the RNR model does consider motivation and the strengths of the offender
A number of reviews have addressed the effectiveness of psychological interventions for
MDOs, focusing on outcomes related to antisocial and offending behaviours. McGuire
reviewed interventions for reducing aggression and violence and concluded that personal
violence can be reduced by psychosocial interventions which include approaches such as
social problem-solving and interpersonal skills [136]. The RNR model was advocated to
improve targeting [136]. McGuire called for more RCTs to improve the evidence based but
also highlighted the need for practical trials [136]. RCTs should be registered at inception and
reported to a sufficient standard [137].
A more recent review of interventions for reducing aggression and violence found that modified
forms of Reasoning and Rehabilitation (R&R) in forensic settings had completion rates
approaching 80%, and that R&R and Cognitive Behaviour Therapy showed the most promise
[138]. However, outcomes are often assessed over short periods and there is little evidence
of the long-term outcomes [138]. The one, small scale, RCT of a R&R cognitive skills
programme for MDOs within Rampling and colleagues’ review found lower levels of verbal
aggression but no difference in violence compared to MDOs who received treatment as usual
(TAU) [139]. However, half did not complete treatment and completers fared better than non-
completers [139]. Other authors have described that starting but not completing treatment
results in worse outcomes than never starting treatment at all [9,10].
Therapies which help to improve an individual’s engagement and communication skills can be
beneficial before addressing offence related programmes. For example, cognitive remediation
therapy has been shown improve working memory, processing speed and attention in people
with schizophrenia [140]. Other therapies such as music therapy, which encompasses a
variety of music making interventions, have been associated with improvements in
communication, social skills and confidence [141,142]. For example, prisoners who have not
engaged in other therapies have participated in music therapy but its efficacy has not been
evaluated in an RCT [142].
A systematic review of interventions for women offenders found that interventions which
address early trauma and comorbid substance misuse had the most utility [143]. Bartlett and
colleagues described the need for more robust evidence and more studies of community
settings where most women offenders are based [143]. Moloney and Moller outlined good
practice on the mrntal health of women in prison settings and also identified the importance of
trauma-focused work to help meet the needs of women [144].
Looking at interventions for specific offences, the CBT-based Sex Offender Treatment and
Evaluation Project (SOTEP; [145]) was well-designed, comprehensive and long-term, yet,
found no difference in the rate of reoffending between the treated and the control group [146].
Post-hoc analyses found that individuals who met the SOTEP programme’s treatment goals
had lower rates of reoffending than those who did not [147]. However, systematic reviews of
psychological interventions for sex offenders have called for more methodological rigour [146,
148, 149] and further randomised trials [146]. Recommendations included not including people
who have dropped out of treatment as controls [148]. A meta-analysis of psychological
treatments for sexual offenders against children found studies with acceptable methodologies
did not provide evidence of treatment efficacy and poor quality studies raised the effect size
[149]. A Cochrane Review of psychological treatments for sex offenders identified ten studies
involving 944 men although some excluded MDOs [146]. However, little information was
available on the primary outcome of reoffending. The follow-up periods were generally short
particularly given that sex offenders have low rates of reconviction and need to be followed up
for sufficient time. A recent review of the prison-based Core Sex Offender Treatment
Programme (SOTP) on the re-offending in England and Wales reported disappointing findings
with little or no difference in reconvictions between treated and untreated sex offenders. Mews
and colleagues found that treated sex offenders were significantly more likely than matched
controls to be reconvicted of a sexual offence and more likely to be reconvicted of a child
image offence, with an average follow-up of 8.2 years [150].
Interventions aimed at specific disorders have been reviewed in a number of meta-analysis.
For example, Yoon and colleagues identified a modest effect for CBT and mindfulness-based
therapies for depression and anxiety in prisoners [151].
A review of 27 RCTs of psychological treatments for people with personality disorder found
some evidence of positive improvements with DBT, emotion regulation group interventions,
and psychoanalytically oriented partial hospitalisation for borderline PD [152]. There was also
some evidence for CBT for avoidant PD and brief adaptive psychotherapy, short-term dynamic
psychotherapy, and manual-assisted CBT treatment for mixed PD [152]. However, Duggan et
al. noted there was much variability in what constitutes TAU [152]. Such methodological
differences and sample heterogeneity restricted [152] or prevented [130] meta-analyses being
conducted. Consensus on suitable outcome measures would improve the comparability of
studies [130]. A more recent review found less evidence in support of treatments for Antisocial
Personality Disorder (AsPD) but Wilson and colleagues cautioned about viewing the disorder
as untreatable due to the low sample size and likely insufficient power [153]. NICE guidance
sets out principles for working with people with AsPD such as having clear pathways in order
to provide the most effective multi-agency care [154, 155]. However, others have called for
more emphasis on the therapeutic relationship [155, 156]. While some evidence reviewed in
this section has been based on non-offending samples, recommendations such as the
importance of therapeutic relationships justify their inclusion. Non-completion of psychological
treatments for people with personality disorder, particularly borderline PD, is particularly
problematic [157]. Strategies are required to build a good therapeutic alliance and different
strategies may be required for different disorders [157].
The treatability of psychopathy remains inconclusive [158]. It is essential to evaluate the
efficacy of treatments, especially in new services. In England, the government established
four pilot sites for offenders with Dangerous and Severe Personality Disorders (DSPD), two in
high secure prisons and two in high secure hospitals. Each pilot site was allowed to determine
its own treatments. Burns and colleagues, as part of one of the commissioned evaluations of
the DSPD service, identified more than 20 different treatments offered across the four sites
[159]. All sites offered psychoeducation and psychological skills based treatments. Individuals
usually participated first in psychoeducation programmes in order to help the individual
understand their personality disorder and become familiar with group work prior to addressing
any offence related programmes. However, not all sites offered programmes to address
specific types of offending (e.g. sex offences). Criticisms of the DSPD initiative included the
initiative being implemented without a consensus on what works [159] and for not selecting
one intervention to test in a randomised trial across the hospital and prison pilot sites [160].
Further, follow-up studies were not possible because of the limited time period [161]. The
DSPD service has been decommissioned without investigating the post-discharge outcomes
of these patients and prisoners. A new offender personality pathway strategy has been
implemented in England, placing more emphasis on treatment within the criminal justice as
opposed to healthcare system [162]. Again, this was implemented without a thorough
evaluation of the evidence base.
Not all treatment modalities have been applied to MDOs; Knabb and colleagues reviewed ten
treatment modalities and found many had not focused on MDO populations or were not able
to address the many complexities [163]. However, the generalisations suggested by Blackburn
for effective treatment programmes for MDOs remain valid. MDOs present with complex
problems which require individualised assessment and treatment formulations and therefore
treatment programmes need to have multiple components to address these problems [124].
Conditions are long-term, requiring continuity of support from secure care and into the
community [124]. Treatment should also attend to the individual’s social functioning and quality
of life [124].
3.5.2 Pharmacological interventions to reduce aggression
Research indicates that staff on forensic wards is exposed to aggressive behaviour at least to
the same extent as staff on acute psychiatric wards, with unprovoked aggression being
particularly prevalent [164]. Preventing aggressive behaviour and the pharmacological
treatment of agitation are key elements guaranteeing the safety of both patients and staff.
Preventing and treating agitation and aggression in forensic patients should take into account
the nature of this group of patients characterised by a chronic course of the disease, long-
lasting stays in hospital, complex morbidity and prior aggressive behaviours. Clinical practice
indicates that agitation and aggression in this group of patients may be related to a number of
factors, including exacerbation of psychotic symptoms, e.g. as a result of discontinuation of
medication, drug resistance, impulsive reactions in people with organic central nervous
system dysfunction or in those with personality disorders, somatic conditions, or the use of
psychoactive substances. Specific factors related to detention in forensic-psychiatric facilities,
such as long-lasting hospitalization, conditions of isolation and restriction, uncertain length of
stay in hospital and overcrowding also contribute to the escalation of conflicts in the group of
patients in long-term confinement.
There is limited research and guidance available regarding the effectiveness of drug treatment
in aggression; of relevance here is the National Institute for Clinical Excellence (NICE)
guidance on the treatment of violence and aggression though this focusses on short-term
management and is not specific to forensic settings [165]. A Cochrane review outlined the
evidence for the treatment of aggression and associated impulsivity with antiepileptics [166].
Further guidance is available on the pharmacological treatment of antisocial and borderline
personality disorders as described below, though, again, recommendations do not take
forensic settings into account separately. Guidance on drug treatment of sex offenders will
also be referred to below. Due to this lack of guidance specific to forensic patients, we draw
here inferences from the research and guidelines relating to non-forensic patient populations
also.
3.5.2.1 Short-term management of aggression
In relation to patients who are acutely agitated and might become aggressive, non-
pharmacological interactions, including, in particular, attempts of verbal deescalation or
providing an appropriate safe environment should be applied as the first-step procedure;
however, if ineffective, pharmacological interventions are recommended [165]. Such acute
interventions, often referred to as rapid tranquillisation, aim to calm the patient down without
causing sleepiness [167]. Pharmacological treatment commenced early may prevent the
application of physical restraint or seclusion, which is traumatic for most patients [168], and
may also reduce the risk to staff caring for the patient [169].
First and second generation antipsychotics, benzodiazepine derivatives (BZDs), their
combination and other sedatives have been used in the acute pharmacological treatment of
aggression. As with other drug treatment, when choosing the appropriate medication, the
patient’s somatic condition and coexisting diseases have to be taken into account; a sudden
deterioration in the general medical condition, including side effects of antipsychotics (e.g.
carbohydrate management disorders, electrolyte imbalances, or malignant neuroleptic
syndrome), and drug interactions have to be considered as the cause of the agitation. Further
considerations include the method of drug administration, the speed of onset of the sedative
effect and, if possible, the patient’s preference [170].
None of the medications fulfil all the criteria of an ‘ideal’ anti-agitation medication though
recommendations can be made on the basis of effectiveness, tolerability and safety. The
recent NICE guidelines on the short-term management of aggression, based on a thorough
systematic review of the literature, recommend the use of intramuscular lorazepam or
intramuscular haloperidol together with intramuscular promethazine for rapid tranquillisation
[165]. It of note that there is no evidence for superior efficacy of the combination of haloperidol
and benzodiazepines over the use of one of these drugs alone. Lorazepam is to be used as
first choice, particularly if little is known about the patient or they have not had antipsychotic
medication before. In people diagnosed with cardiovascular disease or with risk factors of QT
prolongation the application of haloperidol and promethazine should be avoided. Previous
guidance [171] also supported the use of IM olanzapine which has been found to be effective
but carries a risk of serious interaction effects if given concomitant to BZDs (including, among
others, hypotension, bradycardia and respiratory depression) [172].
BZDs are widely used in treating agitation resulting from stimulant intoxication, ethanol
withdrawal, or when the aetiology of agitation is undetermined. Before using benzodiazepines
attention must be paid to the risk of respiratory depression and hypotension, in particular in
people with respiratory conditions or those with alcohol intoxication. Therefore, for agitation
associated with alcohol intoxication, some experts recommend the use of FGA or SGA over
BZDs [172].
After rapid tranquillisation it is necessary to monitor the patient’s level of consciousness, and
monitor basic observation parameters, including heart rate, blood pressure, temperature and
respiration rate, as well possible side effects of the medications used. In forensic (and other)
settings rapid tranquillisation might be used alongside other restrictive measures such as
manual or mechanical restraint or seclusion. Particular attention is to be paid to observations
in these circumstances and restraint in the prone position should be avoided. Individuals
placed in seclusion should be observed continuously.
The difference in utilization of non-pharmacological restrictive measures across Europe
warrants particular mention; e.g. in the UK the use of mechanical restraint is a rare exception
[173] while other countries rarely use seclusion [174]. There seem to be cultural differences
at play here as the evidence base to support the use of one over the other of these measures
is weak and findings relating to patient preference are also mixed [175].
3.5.2.2 Pharmacological prevention of aggression
In addition to managing acute aggression, pharmacological interventions are used to prevent
the occurrence of aggression in the context of different mental disorders. While the evidence
and guidance in this area is to a large extent reflective of good clinical management of specific
psychiatric disorders, we would like to highlight here the evidence in relation to the treatment
of disorders and symptoms particularly associated with aggression. Such treatment does not
only benefit patients but it has also been demonstrated that pharmacological treatment of
psychosis in prison reduced violent recidivism [176].
Data from numerous studies indicate that the risk of aggressive behaviour in people suffering
from psychotic disorders is significantly higher than in the general population as described
above. In the group of patients suffering from schizophrenia spectrum disorders (SSDs)
pharmacological treatment may therefore reduce the risk of violence [177, 178]. The majority
of available data relates to the use of antipsychotic medications, first and second generation
antipsychotics, and relevant guidelines for these disorders should be followed; with regards to
the safety profile, the use of SGA seems preferable though some have questioned this
conclusion [179-181]. In choosing antipsychotic medications, the anticholinergic burden
should also be taken into consideration. Most antipsychotic medications have anticholinergic
properties [182], which has been shown to have a detrimental effect on global cognition and
limiting the patients’ functional capacity and ability to participate in and benefit from
psychosocial treatment programmes [183, 184] thus potentially prolonging patients’ lengths of
stay. Pharmacological interventions should be supported by psychoeducational approaches.
Data in forensic settings supports the use of adherence therapy [185] to build awareness of
the importance of taking medication and prevent relapse due to stopping the medication [186]
particularly as non-adherence to antipsychotic medication has been associated with criminal
recidivism [187]. Alternatively, depot medication has been shown to support compliance and
promote regular service contact in forensic outpatients with a history of non-compliance and
aggression [188].
A significant percentage of patients in forensic psychiatric settings suffer from reduced impulse
control and may be prone therefore to incidents of impulsive aggression. This can occur in the
context of personality disorders, dementia, intellectual disability or other dysfunction of the
central nervous system with various aetiology. Pharmacological prevention of aggression
needs to be primarily directed at treating the underlying diseases, such as, e.g., cholinesterase
inhibitors for neuropsychiatric symptoms in Alzheimer’s disease [189]. In targeting high levels
of impulsiveness specifically, antiepileptics, lithium and selective serotonin reuptake inhibitors
have all been used [190]. However, only antiepileptics have been subject to rigorous
systematic review methodology: A Cochrane review [166] concluded that only four
antiepileptics (valproate/divalproex, carbamazepine, oxcarbazepine and phenytoin) were
effective, compared to placebo, in reducing acts of impulsive aggression. For the management
of agitation and/or aggression in patients with acquired brain injury though, another Cochrane
review found some evidence for the effectiveness of propanolol but not for carbamazepine or
valproate [191]. For Alzheimer’s disease, olanzapine and risperidone have been found to be
effective in the reduction in aggression though they have also attracted most side effects
according to a Cochrane systematic review [192].
The body of evidence is insufficient to allow any definite conclusion to be drawn about
pharmacological interventions in the case of patients presenting with aggression and PD.
There is sparse evidence to support the use of anticonvulsants to reduce aggression in PD
patients, as well as the intensity of subjective states of anger, the readiness to react to anger
(trait–anger) and the tendency to direct anger outwards, and to increase in the ability to control
anger [193]. A Cochrane review on pharmacological interventions in ASPD [194] found some
evidence for the use of nortryptiline and bromocriptine and reported on one trial which found
phenytoin to be effective in reducing impulsive aggression in male prisoners. Some evidence
supports the use of the antipsychotics quetiapine [195, 196], aripiprazole [197], paliperidone
[198] and the anticonvulsants divalproex extended-release [199], topiramate [200] and
lamotrigine [201] in the preventing the aggression among subjects with borderline personality
disorder.
Clozapine warrants attention here as there is some evidence that it might have anti-aggressive
properties. It has been found to be effective in reducing violence in patients with SSD,
particularly in treatment-resistant conditions. Reduction of the clinical severity of ASPD has
been demonstrated in detained patients with ASPD treated with clozapine [202]. A case series
in patients with borderline PD also reported the reduction in aggression [203] and clozapine
has also been associated with reduced re-offending compared to other antipsychotics [204].
However, a systematic review on the subject [205], concluded that in view of a small number
of studies it remains unclear as to whether clozapine is more effective than other
antipsychotics in reducing aggression.
3.5.2.3 Pharmacological treatment of sex offenders
A Cochrane Review of pharmacological interventions for sex offenders identified only seven
trials, published over 20 years ago, therefore not including newer drugs currently in use [206].
The authors concluded that their review did not provide sufficient evidence for reducing sexual
recidivism using pharmacological interventions. Despite this such interventions are frequently
used and the guidelines published by the World Federation of Societies of Biological
Psychiatry [207] recommend an algorithm including selective serotonin reuptake inhibitors and
antiandrogens, depending on the level of risk.
4. CONCLUSIONS
Forensic-psychiatric institutions are high-cost, low volume services which pose significant
restrictions on individuals. It is therefore imperative that the practice of forensic psychiatry
follows the highest standards, based on the most recent scientific evidence. In this review we
summarised the evidence and available guidance regarding expert witnessing, risk
assessment, treatment settings and interventions for MDOs. Overall, the evidence base for
forensic psychiatry is weak and future high quality trials are urgently needed in this complex
and doubly stigmatised patient group. Nevertheless, some conclusions can be drawn for the
practice of forensic psychiatry in Europe:
- Forensic-psychiatric care produces better outcomes than incarceration in prison alone
and should therefore be the preferred modality for interventions.
- Service organisation varies widely across Europe, including where services are
delivered (prisons, general or forensic-psychiatric hospitals), how they are organised
(e.g. levels of security), who decides on access to and discharge from services
(governmental bodies, judiciary, medical) and admission criteria (e.g. exclusion of
certain types of individuals). There is insufficient evidence to suggest one model of
care over another at this point, but generally care models which minimise length of
stay and restrictions and allow smooth transitions are to be preferred. In terms of
oversight, it seems important that professionals working in forensic-psychiatric settings
are able to make decisions in the best interest of patients and not be unduly influenced
by political considerations.
- Forensic psychiatrists who give evidence in court need to be aware of their role as
independent expert. They fulfil this role to assist the legal process and not as treating
physicians. Nevertheless, they are governed by their professional bodies and medical
ethics.
- Risk assessment is an important part of forensic psychiatry. Structured tools should be
used for this task. Those based on structured professional judgement (SPJ) are to be
preferred as they allow the identification of treatment targets and plans for the
management of risk rather than its pure description and prediction of future events.
Due to their, at best, moderate performance in risk prediction, practitioners should be
aware of the limitation of the tools available and not use them as sole determinant of
decision making. Protective factors should be taken into account.
- MDOs should be directed towards and diverted into psychiatric care early in the judicial
process wherever possible.
- Community treatment orders as an approach to managing MDOs in the community
cannot currently be recommended on the basis of available evidence.
- MDOs have a range of complex needs and evidence is often limited as to which
interventions might be effective, in particular where comorbidities, such as substance
use disorders, exist. In designing interventions for MDOs practitioners need to draw
from the literature regarding non-offending psychiatric patients as well as that from
offending populations.
- The RNR and GLM are useful frameworks informing care delivery and intervention
programmes with some evidence that programmes adhering to the former produce
better results.
- General elements of the therapeutic milieu include the therapeutic use of security,
mulitidisciplinary working, patient involvement, meaningful activities and quality of life.
- Interventions designed to enhance motivation and engagement are of particular
importance for MDOs.
- CBT based approaches, group and individual, focusing on problem-solving and
interpersonal skills, have the best evidence base for the treatment of MDOs and should
be preferred over other models.
- The evidence base for interventions of sex offenders is weak and on the basis of this
evidence no psychosocial interventions can currently be recommended for this group.
Research is urgently needed to identify effective psychological and psychosocial
interventions for these offenders.
- There is some (weak) evidence for the effectiveness of antipsychotic agents (in
particular clozapine) in reducing aggression and for the use of mood
stabilisers/antiepileptics and antipsychotics in impulsivity.
- The pharmacological treatment for sex offenders includes SSRIs and antiandrogens
thought the evidence base is weak.
- For MDOs in prisons the principle of equivalence should be applied.
- Suicide prevention is crucial in any setting where MDOs are detained and treated.
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Table 1: Search strategies
Search Strategy (all searches run on 24/08/17)
Ovid 1 exp forensic psychiatry/ (38376)
MEDLINE 2 forensic.ti,ab. (31050)
3 ("mentally ill offender$" or (mental adj5 offend$)).ti,ab. (606)
4 or/1-3 (66004)
5 exp guideline/ or exp practice guideline/ (30576)
6 (guideline$ or "best practice$").ti,ab. (245610)
7 exp Clinical Trial/ (822344)
8 exp randomized controlled trials/ (118140)
9 exp double-blind method/ (150869)
10 exp single-blind method/ (25363)
11 exp cross-over studies/ (43146)
12 randomized controlled trial.pt. (475282)
13 clinical trial.pt. (529253)
14 controlled clinical trial.pt. (96050)
15 (clinic$ adj2 trial).mp. (671553)
16 (random$ adj5 control$ adj5 trial$).mp. (624463)
17 (crossover or cross-over).mp. (77353)
18 ((singl$ or double$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (208286)
19 randomi$.mp. (719887)
20 (random$ adj5 (assign$ or allocat$ or assort$ or reciev$)).mp. (202810)
21 Meta-Analysis as Topic/ (16309)
22 Meta-Analysis/ (84529)
23 exp Review Literature as Topic/ (9683)
24 ((comprehensive$ or integrative or systematic$) adj3 (bibliographic$ or
review$ or literature)).mp. (113011)
25 (meta-analy$ or metaanaly$ or "research synthesis" or "literature review").mp.
(179688)
26 or/5-25 (1606546)
27 4 and 26 (3341)
28 limit 27 to (humans and yr="2000 -Current") (2271)
PsycINFO 1 exp forensic psychiatry/ (4209)
2 forensic.ti,ab. (15482)
3 exp MENTALLY ILL OFFENDERS/ (3458)
4 ("mentally ill offender$" or (mental adj5 offend$)).ti,ab. (1424)
5 or/1-4 (19081)
6 exp Treatment Guidelines/ (5812)
7 exp Best Practices/ (4085)
8 (guideline$ or "best practice$").ti,ab. (62114)
9 randomi$.mp. (69343)
10 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (23429)
11 placebo$.mp. (36846)
12 crossover.mp. (6514)
13 exp treatment effectiveness evaluation/ (21850)
14 exp mental health program evaluation/ (1996)
15 (random$ adj (assign$ or allocate$)).mp. (35339)
16 exp "literature review"/ (22332)
17 ((comprehensive$ or integrative or systematic$) adj3 (bibliographic$ or
review$ or literature)).mp. (31739)
18 (meta-analy$ or metaanaly$ or "research synthesis" or "literature review").mp.
(68037)
19 or/6-18 (277455)
20 5 and 19 (1735)
21 limit 20 to (human and yr="2000 -Current") (1377)
Embase 1 exp forensic psychiatry/ (12753)
2 forensic.ti,ab. (47050)
3 ("mentally ill offender$" or (mental adj5 offend$)).ti,ab. (835)
4 or/1-3 (55396)
5 exp practice guideline/ (422685)
6 (guideline$ or "best practice$").ti,ab. (425150)
7 exp randomized-controlled-trial/ (467945)
8 exp randomization/ (75276)
9 exp single-blind-procedure/ (29106)
10 exp double-blind-procedure/ (142128)
11 exp crossover-procedure/ (53000)
12 (clin$ adj2 trial).mp. (1381324)
13 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).mp. (262261)
14 (random$ adj5 (assign$ or allocat$)).mp. (156308)
15 randomi$.mp. (987540)
16 crossover.mp. (84299)
17 exp Meta Analysis/ (132249)
18 ((comprehensive$ or integrative or systematic$) adj3 (bibliographic$ or
review$ or literature)).mp. (237954)
19 (meta-analy$ or metaanaly$ or "research synthesis" or "literature review").mp.
(297871)
20 or/5-19 (2755269)
21 4 and 20 (3052)
22 limit 21 to (human and yr="2000-Current") (2265)
Cochrane 1 MeSH descriptor: [Forensic Psychiatry] explode all trees (209)
2 forensic:ti,ab,kw (366)
3 ("mentally ill offenders" or (mental near/5 offend*)):ti,ab,kw (43)
4 #1 or #2 or #3 (550)
5 MeSH descriptor: [Guideline] explode all trees (26)
6 MeSH descriptor: [Practice Guideline] explode all trees (16)
7 (guideline* or "best practice*"):ti,ab,kw (20551)
8 #5 or #6 or #7 (20551)
9 #4 and #8 (14)
Limited to Publication Year from 2000 to 2017, in Cochrane Reviews (Reviews and
Protocols), Other Reviews and Trials (9)
